Jobs search

Fractional Product Marketing Lead

StratifAI • Contract • New York, New York, United States • 23h ago

Your mission

Define positioning and messaging for the test, by audience: pathologists, oncologists, lab directors and hospital administrators.
Build the core sales kit: pitch deck, clinical one-pagers, reimbursement summary and objection handling.
Translate our scientific publications and validation data into claims that are accurate and compelling.
Set up the website and digital presence for commercial launch in the US.
Make our presence at key oncology congresses such as SABCS, AACR and ASCO worth remembering: sharp messaging, strong data presentations and follow-up that turns conversations into leads.
Gather competitive and customer insight and feed it back to sales and product.

What success looks like after 6 months

Positioning messaging agreed and in use by sales.
A complete sales kit and a US launch website live for our first diagnostic, Polaris™ Breast.
A congress and content plan for the next 12 months.

Your profile

7+ years of product marketing in diagnostics, ideally oncology or genomic testing.
Experience launching a lab test or diagnostic product to hospitals and clinicians in the US.
You can turn clinical study data into clear, compliant claims.
Familiarity with AI or digital pathology is a plus.
You work independently and deliver in a fractional setup.

Why us?

Building the brand and story of a new AI diagnostics company from the start.
A defined scope with flexible time, and the option to grow the role as we scale.
Direct work with the CEO, and an interdisciplinary scientific team including an advisory board of world-class oncologists and key opinion leaders.
Office space in the heart of Manhattan.

About us

StratifAI is an innovative precision oncology startup developing the next generation of multimodal AI-based cancer biomarkers, with offices in Berlin and New York. Our products are developed with data that is collected in routine patient care, such as histology slides, clinical variables, and longitudinal outcome data. This enables us to develop and provide our biomarkers at scale, allowing cancer patients globally to receive the right treatment at the right time. Our first product, Polaris™ Breast, assesses the risk of distant metastasis at 5- and 10-years for patients with early breast cancer and is expected to be available for clinical use in Q1 2027 on the US as laboratory-developed test.